4-Piperidino-benzolsulfonsaeureamid | 10338-60-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-Piperidino-benzolsulfonsaeureamid
• 英文别名: 4-piperidin-1-yl-benzenesulfonamide；4-(Piperidin-1-YL)benzenesulfonamide；4-piperidin-1-ylbenzenesulfonamide
• CAS: 10338-60-0
• 化学式: C₁₁H₁₆N₂O₂S
• 分子量: 240.326
• InChiKey: ZVFUVTSBLLDOHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS<br/>[FR] COMPOSES DE 4-AMINOPYRIDO[2,3-D]PYRIMIDINE A DISUBSTITUTION 5,7
  申请人：ABBOTT LAB

  公开号：WO2000023444A1

  公开（公告）日：2000-04-27

  A method of inhibiting adenosine kinase by administering one of more compounds of formula (I), wherein R?1, R2, R3 and R4¿ are defined, a pharmaceutical composition comprising a therapeutically effective amount of a compound thereof above in combination with a pharmaceutically acceptable carrier, and a method of treating cerebral ischemia, epilepsy, nociperception, inflammation and sepsis in a mammal in need of such treatment, comprising administering to the mammal a therapeutically effective amount of a compound thereof, a process for preparing said compounds, and compounds having the above formula wherein R?1, R2, R3 and R4¿ are separately defined.

  一种通过给予式(I)中的一个或多个化合物来抑制腺苷激酶的方法，其中R1、R2、R3和R4被定义，以及包含上述化合物的治疗有效量与药学可接受载体组合的制药组合物，以及一种治疗哺乳动物的脑缺血、癫痫、疼痛感知、炎症和败血症的方法，包括给予哺乳动物上述化合物的治疗有效量，制备上述化合物的方法以及具有上述式中R1、R2、R3和R4分别被定义的化合物。
• Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US10208081B2

  公开（公告）日：2019-02-19

  The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

  本发明提供了式 I 的化合物、 包含这些化合物的药物组合物，以及使用这些化合物预防或治疗 FXR 介导或 TGR5 介导的疾病或病症的方法。
• Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use Thereof
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20160176917A1

  公开（公告）日：2016-06-23

  The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
• BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20160185815A1

  公开（公告）日：2016-06-30

  The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
• [EN] BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS D'ACIDE BILIAIRE UTILISÉS COMME AGONISTES DE FXR/TGR5 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ENANTA PHARM INC

  公开号：WO2016086134A1

  公开（公告）日：2016-06-02

  The present invention provides compounds of amino-substituted bile acid compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions. In another embodiment, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound or combination of compounds of the present invention, or a pharmaceutically acceptable salt form, stereoisomer, solvate, hydrate or combination thereof, in combination with a pharmaceutically acceptable carrier or excipient.